Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

被引：11

作者：

Zeidan, Amer M. ^{[1
,2
]}

Schuster, Michael W. ^{[3
]}

Krauter, Jurgen ^{[4
]}

Maertens, Johan A. ^{[5
]}

Gyan, Emmanuel ^{[6
]}

Joris, Magalie ^{[7
]}

Menne, Tobias F. ^{[8
]}

Vyas, Paresh ^{[9
]}

Ma, Weidong Wendy ^{[10
]}

O'Connell, Ashleigh ^{[10
]}

Zeremski, Mirjana ^{[10
]}

Kudla, Arthur ^{[10
]}

Chan, Geoffrey

Sekeres, Mikkael A. ^{[11
]}

机构：

[1] Yale Sch Med, New Haven, CT USA

[2] Yale Canc Ctr, New Haven, CT USA

[3] Stony Brook Univ Hosp, Canc Ctr, Stony Brook, NY USA

[4] Med Klinikum Braunschweig GmbH, Dept Internal Med 3, Braunschweig, Germany

[5] UZ Leuven, Leuven, Belgium

[6] CHU Tours, Hop Bretonneau, Tours, France

[7] CHU Amiens Picardie, Amiens, France

[8] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England

[9] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England

[10] Pfizer Oncol, New York, NY USA

[11] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-124034

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3916

引用

页数：5

共 50 条

[21] The comparative effectiveness of glasdegib in combination with low-dose cytarabine versus azacitidine by bone marrow blasts counts among patients with newly-diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. [J].

van Beekhuizen, Sophie ;

Hu, Yannan ;

Gezin, Ana ;

Heeg, Bart ;

Bell, Timothy ;

Charaan, Majed ;

Brown, Andrew ;

Chan, Geoffrey ;

Cappelleri, Joseph C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[22] Clofarabine and Low-Dose Cytarabine Combination in Relapsed/Refractory Acute Myeloid Leukemia Patients with High Risk Features [J].

Vigil, Carlos ;

Jahan, Nusrat ;

Paun, Oana ;

Weis, Jennifer ;

Heckman, Kevin ;

Silverman, Margarida ;

Carter, Thomas .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 :S297-S297

[23] Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine [J].

W., Keith ;

Pratz ;

Panayiotidis, Panayiotis ;

Recher, Christian ;

Wei, Xudong ;

Jonas, Brian A. ;

Montesinos, Pau ;

Ivanov, Vladimir ;

Schuh, Andre C. ;

Dinardo, Courtney D. ;

Novak, Jan ;

Pejsa, Vlatko ;

Stevens, Don A. ;

Yeh, Su-Peng ;

Kim, Inho ;

Turgut, Mehmet ;

Fracchiolla, Nicola ;

Yamamoto, Kazuhito ;

Ofran, Yishai ;

Wei, Andrew H. ;

Bui, Cat ;

Benjamin, Katy ;

Kamalakar, Rajesh ;

Potluri, Jalaja ;

Mendes, Wellington ;

Devine, Jacob ;

Fiedler, Walter .

BLOOD, 2020, 136

[24] Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia [J].

Fujino, Keita ;

Ureshino, Hiroshi ;

Yoshida, Tetsumi ;

Ichinohe, Tatsuo .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)

[25] VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IMPROVE THE REMISSION RATE IN OLDER OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA [J].

Han, Xiao ;

Song, Qingxiao ;

Wan, Kai ;

Zhang, Mengyun ;

Liu, Xue ;

Yan, Hongju ;

Zhang, Cheng ;

Wen, Qin ;

Zhang, Xi .

BONE MARROW TRANSPLANTATION, 2024, 59 :176-177

[26] Venetoclax Combined with Azacitidine or low-dose Cytarabine for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplant [J].

Smith, Katy ;

Fathoala, Dina ;

Anthias, Chloe ;

Easdale, Sandra ;

Ethell, Mark ;

Potter, Mike ;

Mir, Farheen ;

Taussig, David ;

Nicholson, Emma .

BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) :188-189

[27] Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review [J].

Amador-Medina, Lauro Fabian ;

Crespo-Solis, Erick ;

Turrubiates-Herna, Francisco Javier ;

Santibanez-Bedolla, Karla Edith .

HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 :S322-S331

[28] Improved Outcomes of Low-Dose Cytarabine Regimen By Increased Dose and Duration of Cytarabine in Combination with Oral Etoposide for Elderly Acute Myeloid Leukemia [J].

Shin, Seung-Hwan ;

Yahng, Seung-Ah ;

Yoon, Jae-Ho ;

Cho, Byung-Sik ;

Kim, Hee-Je ;

Jeon, Young-Woo ;

Lee, Sung-Eun ;

Eom, Ki-Sung ;

Kim, Yoo-Jin ;

Lee, Seok ;

Min, Chang-Ki ;

Cho, Seok-Goo ;

Kim, Dong-Wook ;

Lee, Jong-Wook ;

Min, Woo-Sung .

BLOOD, 2015, 126 (23)

[29] Low-Dose Cytarabine With or Without Glasdegib in Newly Diagnosed Patients with Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial [J].

Papayannidis, Cristina ;

Smith, B. Douglas ;

Heuser, Michael ;

Montesinos, Pau ;

Sekeres, Mikkael A. ;

Oriol, Albert ;

Schiller, Gary ;

Candoni, Anna ;

Jamieson, Catriona ;

Hoang, Caroline J. ;

Ma, Weidong Wendy ;

Zeremski, Mirjana ;

O'Connell, Ashleigh ;

Chan, Geoffrey ;

Cortes, Jorge E. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 :S228-S229

[30] More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine [J].

Aldoss, Ibrahim ;

Marcucci, Guido .

CHINESE CLINICAL ONCOLOGY, 2019, 8

← 1 2 3 4 5 →